1. Home
  2. ADPT vs PCN Comparison

ADPT vs PCN Comparison

Compare ADPT & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • PCN
  • Stock Information
  • Founded
  • ADPT 2009
  • PCN 2001
  • Country
  • ADPT United States
  • PCN United States
  • Employees
  • ADPT N/A
  • PCN N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • PCN Investment Managers
  • Sector
  • ADPT Health Care
  • PCN Finance
  • Exchange
  • ADPT Nasdaq
  • PCN Nasdaq
  • Market Cap
  • ADPT 929.8M
  • PCN 781.6M
  • IPO Year
  • ADPT 2019
  • PCN N/A
  • Fundamental
  • Price
  • ADPT $6.81
  • PCN $13.49
  • Analyst Decision
  • ADPT Buy
  • PCN
  • Analyst Count
  • ADPT 4
  • PCN 0
  • Target Price
  • ADPT $6.75
  • PCN N/A
  • AVG Volume (30 Days)
  • ADPT 1.3M
  • PCN 218.7K
  • Earning Date
  • ADPT 02-12-2025
  • PCN 01-01-0001
  • Dividend Yield
  • ADPT N/A
  • PCN 9.73%
  • EPS Growth
  • ADPT N/A
  • PCN N/A
  • EPS
  • ADPT N/A
  • PCN N/A
  • Revenue
  • ADPT $177,282,000.00
  • PCN N/A
  • Revenue This Year
  • ADPT $6.48
  • PCN N/A
  • Revenue Next Year
  • ADPT $18.72
  • PCN N/A
  • P/E Ratio
  • ADPT N/A
  • PCN N/A
  • Revenue Growth
  • ADPT N/A
  • PCN N/A
  • 52 Week Low
  • ADPT $2.28
  • PCN $10.70
  • 52 Week High
  • ADPT $7.46
  • PCN $14.48
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 54.92
  • PCN 44.08
  • Support Level
  • ADPT $5.98
  • PCN $13.23
  • Resistance Level
  • ADPT $7.28
  • PCN $13.56
  • Average True Range (ATR)
  • ADPT 0.54
  • PCN 0.13
  • MACD
  • ADPT -0.00
  • PCN 0.01
  • Stochastic Oscillator
  • ADPT 58.06
  • PCN 68.42

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About PCN Pimco Corporate & Income Strategy Fund

PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.

Share on Social Networks: